An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte srebp-regulated genes

International Journal of Biological Sciences

Volumn 8, Issue 3, 2012, Pages 310-327

  Zhang, Liwen ^a   McCabe, Timothy ^a   Condra, Jon H ^a   Ni, Yan G ^a   Peterson, Laurence B ^a   Wang, Weirong ^a   Strack, Alison M ^a   Wang, Fubao ^a   Pandit, Shilpa ^a   Hammond, Holly ^a   Wood, Dana ^a   Lewis, Dale ^a   Rosa, Ray ^a   Mendoza, Vivienne ^a   Cumiskey, Anne Marie ^a   Johns, Douglas G ^a   Hansen, Barbara C ^e   Shen, Xun ^a   Geoghagen, Neil ^a   Jensen, Kristian ^a   Zhu, Lei ^a   Wietecha, Karol ^a   Wisniewski, Douglas ^a   Huang, Lingyi ^a   Zhao, Jing Zhang ^a   Ernst, Robin ^a   Hampton, Richard ^a   Haytko, Peter ^a   Ansbro, Frances ^a   Chilewski, Shannon ^a   Chin, Jayne ^a   Mitnaul, Lyndon J ^a   Pellacani, Andrea ^b   Sparrow, Carl P ^a   An, Zhiqiang ^a,c   Strohl, William ^a,d   Hubbard, Brian ^a   Plump, Andrew S ^a   Blom, Daniel ^a   Sitlani, Ayesha ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Department of MBV and Early Biologics ^*  (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d CENTOCOR INC   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Hypercholesterolemia; LDL receptor; Low density lipoprotein cholesterol (LDL C); PCSK9; Primary hepatocytes; Sterol regulatory element binding protein (SREBP)

Indexed keywords

CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PCSK9 PROTEIN, MOUSE; RECOMBINANT PROTEIN; SERINE PROTEINASE; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ANIMAL; ANTIBODY AFFINITY; ARTICLE; BIOSYNTHESIS; BLOOD; CELL CULTURE; CELL STRAIN HEPG2; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LIPID METABOLISM; LIVER; LIVER CELL; MACACA MULATTA; METABOLIC SYNDROME X; METABOLISM; MOUSE; PASSIVE IMMUNIZATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTICHOLESTEREMIC AGENTS; CELLS, CULTURED; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNIZATION, PASSIVE; LIPID METABOLISM; LIVER; MACACA MULATTA; METABOLIC SYNDROME X; MICE; MICE, TRANSGENIC; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RECOMBINANT PROTEINS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84863116753     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3524     Document Type: Article

References (46)

1. Ferrieres J, Berard E, Crisan O, and Bongard V. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution. Arch Cardiovasc Dis 2010;103: 302-309.
2. Franks P, Tancredi D, Winters P, and Fiscella K. Cholesterol treatment with statins: who is left out and who makes it to goal? BMC Health Serv Res 2010;10:68.
3. Toutouzas K, Drakopoulou M, Skoumas I, and Stefanadis C. Advancing therapy for hypercholesterolemia. Expert Opin Pharmacother 2010;11: 1659-1672.
4. Eckel R.H. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95: 2015-2022.
5. Abifadel M, Pakradouni J, Collin M, Samson-Bouma M.E, Varret M, Rabes J.P, and Boileau C. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat. 2010;20: 1547-71.
6. Costet P. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther 2010;126: 263-278.
7. Li H, Ziegler N, Cui R, and Liu J. Recent patents on PCSK9: a new target for treating hypercholesterolemia. Recent Pat DNA Gene Seq 2009;3: 201-212.
8. Cao G, Qian Y.W, Kowala M.C, and Konrad R.J. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocr Metab Immune Disord Drug Targets 2008;8: 238-243.
9. Seidah N.G. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009;13: 19-28.
10. Costet P, Krempf M, and Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 2008;33: 426-434.
11. Lambert G, Charlton F, Rye K.A, and Piper D.E. Molecular basis of PCSK9 function. Atherosclerosis 2009;203: 1-7.
12. Horton J.D, Cohen J.C, and Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007;32: 71-77.
13. Duff C.J, Scott M.J, Kirby I.T, Hutchinson S.E, Martin S.L, and Hooper N.M. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J 2009;419: 577-584.
14. Cohen J.C, Boerwinkle E, Mosley T.H, Jr, and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354: 1264-1272.
15. Cohen J, Pertsemlidis A, Kotowski I.K, Graham R, Garcia C.K, and Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37: 161-165.
16. Kotowski I.K, Pertsemlidis A, Luke A, Cooper R.S, Vega G.L, Cohen J.C, and Hobbs H.H. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006;78: 410-422.
17. Abifadel M, Varret M, Rabes J.P, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34: 154-156.
18. Huang C.C, Fornage M, Lloyd-Jones D.M, Wei G.S, Boerwinkle E, and Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet 2009;2: 354-361.
19. Kathiresan S, Voight B.F, Purcell S, Musunuru K, Ardissino D, Mannucci P.M, Anand S, Engert J.C, Samani N.J, Schunkert H, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009;41: 334-341.
20. Rashid S, Curtis D.E, Garuti R, Anderson N.N, Bashmakov Y, Ho Y.K, Hammer R.E, Moon Y.A, and Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005;102: 5374-5379.
21. Frank-Kamenetsky M, Grefhorst A, Anderson N.N, Racie T.S, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008;105: 11915-11920.
22. Chan J.C, Piper D.E, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009;106: 9820-9825.
23. Ni Y.G, Di Marco S, Condra J.H, Peterson L.B, Wang W, Wang F, Pandit S, Hammond H.A, Rosa R, Cummings R.T, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol. J Lipid Res 2011;52: 78-86.
24. Fasano T, Sun X.M, Patel D.D, and Soutar A.K. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis 2009;203: 166-171.
25. Zhang D.W, Garuti R, Tang W.J, Cohen J.C, and Hobbs H.H. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 2008;105: 13045-13050.
26. Zhang D.W, Lagace T.A, Garuti R, Zhao Z, McDonald M, Horton J.D, Cohen J.C, and Hobbs H.H. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282: 18602-18612.
27. Fisher T.S, Lo Surdo P, Pandit S, Mattu M, Santoro J.C, Wisniewski D, Cummings R.T, Calzetta A, Cubbon R.M, Fischer P.A, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 2007;282: 20502-20512.
28. Ni Y.G, Condra J.H, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley M.J, Ruggeri L, Cummings R.T, Cubbon R.M, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 2010;285:12882-12891.
29. Fan D, Yancey P.G, Qiu S, Ding L, Weeber E.J, Linton M.F, and Fazio S. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 2008;47: 1631-1639.
30. Poirier S, Mayer G, Poupon V, McPherson P.S, Desjardins R, Ly K, Asselin M.C, Day R, Duclos F.J, Witmer M, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 2009;284: 28856-28864.
31. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, and Seidah N.G. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283: 2363-2372.
32. Cameron J, Holla O.L, Ranheim T, Kulseth M.A, Berge K.E, and Leren T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006;15: 1551-1558.
33. Lagace T.A, Curtis D.E, Garuti R, McNutt M.C, Park S.W, Prather H.B, Anderson N.N, Ho Y.K, Hammer R.E, and Horton J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116: 2995-3005.
34. Maxwell K.N, Fisher E.A, and Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005;102: 2069-2074.
35. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin M.C, Hamelin J, Varret M, Allard D, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279: 48865-48875.
36. Salek L, Lutucuta S, Ballantyne C.M, Gotto Jr A.M, and Marian A.J. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med 2002;80: 737-744.
37. Fiegenbaum M, Silveira F.R, Van der Sand C.R, Van der Sand L.C, Ferreira M.E, Pires R.C, and Hutz M.H. Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 2005;5: 359-364.
38. Matsuyama H, Sato K, Nakamura Y, Suzuki K, and Akiba Y. Modulation of regulatory factors involved in cholesterol metabolism in response to feeding of pravastatinor cholesterol-supplemented diet in chickens. Biochim Biophys Acta 2005;1734: 136-142.
39. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, and Marz W. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 2001;62: 1545-1555.
40. Mascaro C, Ortiz J.A, Ramos M.M, Haro D, and Hegardt F.G. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription. Arch Biochem Biophys 2000;374: 286-292.
41. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah N.G, Bernier L, and Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24: 1454-1459.
42. Dong B, Wu M, Li H, Kraemer F.B, Adeli K, Seidah N.G, Park S.W, and Liu J. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010;51: 1486-1495.
43. Welder G, Zineh I, Pacanowski M.A, Troutt J.S, Cao G, and Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010;51: 2714-2721.
44. Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah N.G, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010;51: 140-149.
45. Ding S.Y, Tigno X.T, and Hansen B.C. Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. Metabolism 2007;56: 838-846.
46. Dong B, Wu M, Cao A, Li H, Liu J. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression. Int J Mol Med. 2011;27: 103-110.